Obsidian Therapeutics Short Positions Rise in September
Obsidian Therapeutics had 884,528 shares sold short as of Sept. 30, up 249.5% from 253,084 two weeks earlier. The shorted total was 1.4% of shares, with a 0.9-day cover ratio. The stock traded at $13.00, well below its 52-week high, while analysts still had a Moderate Buy consensus and a $39.00 average target.
Obsidian Therapeutics focuses on engineered cell and gene therapies for serious illnesses. Its CytoDRiVE platform aims to use small molecules to regulate protein expression, potentially improving safety and efficacy in immune-cell treatments, including solid tumor programs and other gene-modulation uses.
As of Sept. 30, short interest reached 884,528 shares, up from 253,084 two weeks earlier. That equaled 1.4% of shares, with 0.9 days to cover. The stock traded at $13.00, within a $12.07–$49.97 yearly range and under its 50-day average of $18.25. Analysts had a Moderate Buy consensus and $39.00 average target.
Rising short interest could signal greater uncertainty around Obsidian Therapeutics, affecting investors through sharper price swings and affecting the company if volatility raises financing costs or complicates capital access. For patients, any funding or research delays might matter indirectly, though short-selling data alone may not predict clinical progress. Analysts’ more optimistic target suggests views remain divided, so the practical impact may depend on upcoming company developments rather than this single metric.